The American College of Clinical Oncology (ASCO) is now seeking feedback related to an upcoming guideline update. The open comment period is for Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update Part 2 - Cardiac, Renal, and Musculoskeletal Adverse Events. Interested individuals will need to agree to a confidentiality agreement before viewing the guideline.
Click here to view the ASCO guideline.
The open comment window closes on August 21, 2026.